Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients.

ABSTRACT:

Introduction

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular prognosis in patients with chronic kidney disease (CKD), diabetes, and heart failure; and slow the decline of kidney dysfunction in patients with albuminuria. Although safety and efficacy of SGLT2i have not been investigated in kidney transplant recipients (KTRs), their marketing authorization leaves the possibility of their use in these patients in France.

Methods

This was a prospective multicenter real-life study including all consecutive KTRs treated with SGLT2i.

Results

We identified 347 KTRs treated with SGLT2i (97% with dapagliflozin), with an initiation of treatment most often beyond the first year after transplantation (87%). Importantly, 226 (65.1%) were diabetic and 245 (7

SUBMITTER: Maigret L 

PROVIDER: S-EPMC11993682 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature